Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety/mechanism and indication-level claims align with label excerpts (e.g., IL-17A mechanism; infection risk and TB/lvaccination cautions). However, many efficacy/timing and frequency phrasing claims are not supported by the provided label excerpts, which include limited efficacy detail and do not support general statements like 'commonly' or specific benefit timelines.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is used for plaque psoriasis.
Indications and Usage: indicated for moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older.
Cosentyx (secukinumab) is used for psoriatic arthritis.
Indications and Usage: indicated for active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older.
Cosentyx affects immune signaling.
Description/Clinical Pharmacology: secukinumab is an IL-17A antagonist that selectively binds IL-17A and inhibits its interaction with the IL-17 receptor.
Cosentyx may make patients more prone to infections such as upper respiratory infections.
Warnings and Precautions (5.1): 'COSENTYX may increase the risk of infections.' (Specific 'upper respiratory infections' not specifically stated in the provided excerpts, but infection-risk claim is supported.)
Patients may watch for warning signs that an infection is worsening (e.g., fever, worsening cough, or feeling significantly unwell) while taking Cosentyx.
Warnings and Precautions (5.1): 'If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.' (The provided excerpts do not list specific signs like fever/cough/unwell, but the monitoring concept for serious infection is supported.)
Some people report injection-site reactions with Cosentyx, such as redness, pain, or swelling.
Label adverse reaction framework includes hypersensitivity and infection/IBD/eczema; however, the provided excerpts do not specifically mention injection-site reactions. This statement is therefore treated as unsupported (see unsupported list), not accurate.
Unsupported Statements
Some people report injection-site reactions with Cosentyx, such as redness, pain, or swelling.
The supplied label excerpts provided for adverse reactions do not mention injection-site reactions or these specific examples.
Some users report general symptoms such as fatigue and headache after starting Cosentyx.
No fatigue/headache adverse reaction frequency or even mention appears in the provided label excerpts.
Some users track new rashes and persistent diarrhea as possible symptoms after starting Cosentyx.
While eczema-like severe skin reactions and IBD/IBD flare-ups are mentioned, 'persistent diarrhea' as a counseling item and 'new rashes' as a symptom tracking suggestion are not explicitly supported in the provided excerpts.
Users generally expect improvements in symptoms related to their condition when taking Cosentyx.
The label excerpts provided do not include patient-expectation language; efficacy claims are not quoted with sufficient support.
Users commonly report skin improvement in plaque psoriasis with Cosentyx, including reduced plaque thickness and scaling over time.
The provided excerpts include indications but do not provide the specific efficacy outcome wording (plaque thickness/scaling) or 'commonly' frequency.
Users commonly report smoother skin patches over time with Cosentyx for plaque psoriasis.
No such phrasing or frequency/outcome is provided in the excerpted label content.
Users commonly report less itch and irritation compared with before treatment with Cosentyx for plaque psoriasis.
No itching/irritation efficacy outcomes or frequency are present in the provided label excerpts.
Users taking Cosentyx for psoriatic arthritis commonly report less joint pain and swelling.
No specific PsA efficacy outcomes or frequency language (e.g., joint pain/swelling) is provided in the excerpted label content.
Users taking Cosentyx for psoriatic arthritis commonly report improved morning stiffness.
Morning stiffness outcome and frequency are not present in the provided label excerpts.
Users taking Cosentyx for psoriatic arthritis commonly report better ability to do everyday activities.
No patient function/activity outcome is provided in the excerpted label content.
Many people report early changes after starting Cosentyx and more meaningful symptom relief later as the drug reaches steady effect.
No timing/steady-effect explanation or specific timeline language is included in the provided label excerpts.
The timeline of Cosentyx benefits depends on diagnosis (psoriasis vs psoriatic arthritis vs others).
The provided excerpts do not include comparative timing-by-diagnosis counseling or trial timing results.
The timeline of Cosentyx benefits depends on dose and whether it is started with an initial loading regimen.
Label excerpts provided include 'with a loading dosage' vs 'without a loading dosage' dosing schedules, but do not provide benefit-timing counseling tied to loading regimen.
The timeline of Cosentyx benefits depends on baseline severity and how long symptoms have been present.
No label excerpt supports counseling that baseline severity/duration drives benefit timing.
Some users who switch to Cosentyx after an inadequate response to earlier treatment may report strong symptom control.
No label excerpt supports switch-after-failure counseling or describes symptom control likelihood.
Some users who switch to Cosentyx after inadequate response to earlier treatment may report slower or smaller improvement.
No label excerpt supports switch-after-failure outcome expectations.
When users report Cosentyx is working, they usually refer to fewer visible plaques (psoriasis).
No label excerpt provides patient-surrogate descriptions like 'fewer visible plaques' or 'usually' language.
When users report Cosentyx is working, they usually refer to less pain and stiffness (arthritis).
No label excerpt supports this patient-report interpretation language or frequency.
When users report Cosentyx is working, they usually refer to fewer flare-ups.
No label excerpt provides this 'usually' phrasing.
When users report Cosentyx is working, they usually refer to improved function and comfort in daily life.
No label excerpt supports this patient-report interpretation language.
Because Cosentyx modulates immune pathways, users focus on infection risk.
The label supports infection risk, but does not include this user-focus/counseling phrasing.
Users focus on whether they can receive vaccines safely while taking Cosentyx.
The label excerpt supports avoiding live vaccines, but does not state this as a 'user focus' item.
Users focus on what to do if they get sick while on Cosentyx.
The label supports monitoring and discontinuation for serious infection, but does not provide general 'what to do if sick' counseling phrased this way in the excerpts.
Patients may track how long benefits last when they miss doses of immune-modulating drugs like Cosentyx.
The provided excerpts do not address missed-dose counseling, duration of benefits after missed doses, or tracking instructions.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
For infection risk, label excerpt supports TB evaluation and latent TB treatment prior to initiation; and avoiding live vaccines. None of these specific on-label pre-treatment/avoid-live-vaccine elements are explicitly stated in the AI claims (only a general vaccine-safety focus is mentioned).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Main safety-related claims are directionally aligned (infection risk; monitor serious infections; immune mechanism). However, multiple unsupported efficacy/timing claims with 'commonly' frequency may mislead expectations, and the AI does not explicitly reflect some label-specific safety steps (e.g., TB evaluation/latent TB treatment; avoid live vaccines) beyond a generalized vaccine focus.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many statements about how often patients experience specific symptoms/outcomes and the timeline/steady-state of benefit are not supported by the provided label excerpts.
Suggested Improvement
Limit claims to label-supported content in provided excerpts (indications; IL-17A mechanism; infection risk; monitor serious infections; TB evaluation; avoid live vaccines; hypersensitivity/IBD/eczema warnings) and remove or qualify unsourced frequency/timing and patient-expectation narratives.